secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001193125-24-077930
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01, 5.02, 2.02, 2.03, 3.02, 3.03, 4.01, 5.01, 5.03, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio completes reverse merger with Homology Medicines; raises $42M in pre-closing financing
--------------------------------------------------------------------------------

- Merger closed March 25, 2024; former Homology renamed Q32 Bio Inc., trading as QTTB on Nasdaq.
- Pre-closing financing of $42M (35M shares at ~$1.20/share) from accredited investors.
- Homology stockholders receive one CVR per share for potential payments from legacy asset sales (HMI-103, etc.).
- New board and officers installed; lock-up agreements for 180 days for certain stockholders and executives.
- Post-merger shares outstanding ~11.93M; reverse stock split 1:18 effected March 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524077930/0001193125-24-077930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524077930/d811189d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-077930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer